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The renin-angiotensin system blockade does not prevent renal
interstitial fibrosis induced by aristolochic acids.
Background. Experimental aristolochic acid nephropathy
(AAN), characterized by interstitial fibrosis, tubular atrophy,
and chronic renal failure, was reported after 35-day injections
of aristolochic acids (AA) to salt-depleted male Wistar rats.
The link between renal fibrosis and the renin-angiotensin sys-
tem (RAS) in this model remains unknown.
Methods. We investigated the impact of sodium diets (low
and normal), of RAS inhibition with enalapril (ENA) alone, or
combined with candesartan (CSN) for 35 days, and ENA + CSN
for 65 days on AAN development. At the end of each obser-
vation period, blood pressure and renal angiotensin-converting
enzyme activity were measured, as well as renal functional im-
pairment (plasma creatinine increase, proteinuria) and histo-
logic lesions (interstitial fibrosis, monocytes/macrophages infil-
tration, myofibroblasts collagens type I and IV, proliferating
cells).
Results. Sodium intake did not modify renal functional and
morphologic impairment induced by AA. The RAS blockade
by ENA or ENA + CSN in rats receiving AA did not result in
any statistical difference in terms of renal failure, proteinuria,
and interstitial fibrosis on day 35 or 65. On day 35, the mono-
cytes/macrophages infiltration was significantly decreased by
two-fold when ENA (P < 0.01) or ENA + CSN (P < 0.01) was
given from day 0.
Conclusion. Our data demonstrate that RAS modulation by
salt depletion and pharmacologic blockade do not influence re-
nal failure and interstitial fibrosis in the rat model of AAN.
We suggest that pathways of interstitial renal fibrosis may be
independent of RAS at least in some conditions.
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Irrespective of the underlying cause, chronic renal dis-
eases are characterized by progressive interstitial fibrosis
and an increasing loss of renal tubules. It has been largely
demonstrated that the renal function decline and long-
term prognosis are well correlated with the severity of
tubulointerstitial injuries [1, 2]. Regular intake of Chinese
medicinal herbs containing nephrotoxic and carcinogenic
aristolochic acids (AA) is now recognized as a cause of
interstitial renal fibrosis, as well as a risk factor for up-
per urinary tract carcinoma in humans [3–9]. Taking into
account that a first attempt to experimentally reproduce
the disease in rodents had failed [10], we successfully de-
veloped a rat model of AA nephropathy (AAN) derived
from the experimental model of cyclosporine nephropa-
thy [11]. Both models include a salt depletion before the
exposure to the nephrotoxic substance [11, 12], leading to
the hypothesis that the renin-angiotensin system (RAS)
could play an important role in the pathophysiology of
renal fibrosis.
Large clinical trials reinforced this hypothesis by
demonstrating renoprotective effects of angiotensin-
converting enzyme (ACE) inhibitors or angiotensin type
1 receptor antagonists (AT1RA) on the progression of di-
abetic [13, 14], as well as nondiabetic, renal diseases [15,
16]. Recent short-term studies indicated that AT1RA ex-
hibited antiproteinuric and antihypertensive effects simi-
lar to those primarily shown by ACE inhibitors in patients
with chronic renal diseases [17, 18]. Moreover, these reno-
protective effects seemed to be more pronounced when
ACE inhibitors and AT1RA therapy were combined [19].
Experimentally, the RAS blockade with ACE inhibitors
or AT1RA was reported to reduce chronic renal lesions
in some animal models, such as remnant kidney [20],
streptozotocin-induced diabetes mellitus [21, 22], hyper-
tensive renal injury [23], or unilateral ureteral obstruction
[24]. This led us to speculate that angiotensin II (Ang II)
could play a key role in the fibrotic process of AA-induced
nephropathy.
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Table 1. Study design
Protocol 1 (35 days) Protocol 2 (35 days) Protocol 3 (65 days)
Rat groups N Diet Rat groups N Diet Rat groups N Diet
Control (vehicles) 6 LS Control (vehicles) 7 NS
ENA 7 LS ENA + CSN 7 NS
AA 7 LS AA 6 NS AA for 35 days 6 NS
AA + ENA 7 LS AA + ENA + CSN 7 NS AA for 35 days and ENA + CSN for 65 days 6 NS
AA + ENA from day 10 7 LS AA 7 LS
Abbreviations are: LS, low sodium; NS, normal sodium; ENA, enalapril (10 mg/kg body wt/day, in drinking water); CSN, candesartan cilexetil (7 mg/kg body wt/day
in drinking water); AA, aristolochic acids (10 mg/kg body wt/day, subcutaneous injections for 35 days). Drugs were given from day 0, except when indicated. The rats
were sacrificed on day 35 in protocols 1 and 2, and on day 65 in protocol 3.
We therefore investigated the respective roles of salt
depletion and ACE inhibitors ± AT1RA on the devel-
opment of renal fibrosis in rats treated with AA. Starting
from the initial model of AAN, which is the daily sub-
cutaneous administration of AA for 35 days, enalapril
(ENA) was given either prophylactically (from day 0) or
therapeutically (from day 10) to salt-depleted rats intox-
icated by AA. Because no beneficial effect was observed
[abstract; Debelle FD et al, J Am Soc Nephrol 13:344A,
2002], we performed a second protocol addressing two
questions: first, whether a low sodium diet was mandatory
to enhance the AA-induced renal fibrosis; and second,
whether an optimized RAS blockade with a combined
therapy ACE inhibitor plus AT1RA was beneficial to pre-
vent the progression of this nephropathy. Because no sig-
nificant prevention by dual RAS blockade was observed
after 35 days, we performed a third protocol with a longer
period of observation (65 days). Our experimental data
showed that stimulation of the RAS did not enhance the
renal toxicity of AA, and that the RAS blockade by an
ACE inhibitor ± AT1RA did not affect the progression
of renal failure and interstitial fibrosis, despite a signifi-
cant reduction of the macrophage infiltration. Taken to-
gether, these data suggest that some pathways leading to
interstitial renal fibrosis, such as the pathways involved
in AA-induced nephropathy, may be RAS independent.
METHODS
Experimental design
Male Wistar rats (Elevage Janvier, Le Genest Saint-
Isle, France) weighing 160 to 210 g (age, 5 to 6 weeks) were
housed in a temperature-, humidity-, and light-controlled
environment with free access to water and food. Animal
care and treatment were approved by the Ethical Com-
mittee for Animal Care (Faculty of Medicine, Univer-
site´ Libre de Bruxelles). A mixture of AA, containing
40% aristolochic acid I (AAI) and 60% aristolochic acid
II (AAII), was purchased from Acros Organics (Geel,
Belgium) and dissolved in polyethylene glycol (PEG)
400 (Fluka Chemie, Buchs, Switzerland) to a final con-
centration of 20 mg/mL, and diluted in distilled water
before subcutaneous injection at a dose of 10 mg/kg
body weight. The ACE inhibitor enalapril (ENA; Sigma
Aldrich, Bornem, Belgium) and the AT1RA candesar-
tan cilexetil (CSN; a gift from Astra Zeneca Research
laboratories, Mo¨lndal, Sweden) were prepared as a stock
solution of 200 mg/L and 100 mg/L, respectively, and ad-
ministrated in the drinking water at the daily dosage of
10 mg/kg body weight for enalapril, and 7 mg/kg body
weight for candesartan. Due to its poor solubility in
water, CSN was first solubilized in vehicle comprising
PEG400 (0.1% vol/vol), sodium bicarbonate (5 mmol/L),
and ethanol (0.1% vol/vol). Drinking consumption and
body weight were recorded three times a week for drug
dosage adjustment.
In the first protocol (Table 1), 34 salt-depleted rats
were randomly divided into five groups and submitted
to the following treatments for a 35-day period: the ve-
hicles of AA and ENA (control group); ENA therapy
(ENA group); AA alone (AA group); AA and ENA
(AA+ENA group); and AA and ENA being started
from day 10 (AA+ENAd10 group). As previously de-
scribed [11], the salt depletion was achieved by adminis-
trating a single dose of furosemide (4 mg/kg body wt,
intraperitoneally; Hoechst Marion Roussel, Frankfurt,
Germany) one week before starting the protocol, and
by maintaining animals on a low-sodium, normal-protein
diet (0.05% sodium; Carfil Quality, Oud-Turnhout, Bel-
gium) throughout the study.
In the second protocol (Table 1), weight-matched rats
fed with a normal sodium diet (0.20%) were randomly
assigned to four groups and received the following drugs
for 35 days: the vehicles of AA and ENA+CSN (con-
trol group); ENA+CSN combined therapy (ENA+CSN
group); AA alone (AA group); and AA and ENA+CSN
combined therapy (AA+ENA+CSN group). To assess
the effect of dietary sodium intake on AA-induced
nephropathy, a fifth group was added and consisted
of AA-treated rats after salt depletion conditioning, as
described above. In a third longer-duration protocol
(Table 1), rats intoxicated by AA for 35 days still received
ENA+CSN until day 65 and were compared with AA-
treated rats (N = 6).
At the end of each observation period, systolic blood
pressure (sBP) was noninvasively measured with a mod-
ern electronic version of the sphygmomanometer method
(AH 50–3046; Harvard Apparatus, Ltd., Edenbridge,
Debelle et al: Renin-angiotensin system and aristolochic acid nephropathy 1817
UK), and urine collection was performed by placing
animals in metabolic cages. Afterwards, rats were deeply
anesthetized with ketamine and xylazine, and blood sam-
ples were taken by intracardiac puncture with a syringe
containing potassium-EDTA. Urine and blood samples
were centrifugated at 1600g for 15 minutes at 4◦C and
stored at −20◦C until assayed. Kidneys were quickly re-
moved, decapsulated, and weighed. The right kidney was
hemisected, rinsed in saline, and fixed in 4% buffered
formaldehyde for morphologic studies for one part, and
snap frozen for immunohistochemistry for the other part.
The left kidney was rinsed, put in liquid nitrogen, and
stored at −80◦C for enzyme activity analyses.
Renal biochemical parameters
Plasma creatinine levels were determined by using a
sensitive accurate high-performance liquid chromatog-
raphy (HPLC) method, as previously described [25].
An automated analyzer (Modular Hitachi, Roche Di-
agnostics Division, Vilvoorde, Belgium) was used for
the determination of urinary sodium. Urinary creatinine
and protein levels were measured using the pseudoki-
netic Jaffe´ method (Creatinine Diagnostic Kit, Sigma-
Aldrich, Bornem, Belgium) and the Bradford dye binding
assay [26], respectively. Twenty micrograms of urinary
protein contents were loaded per lane and were elec-
trophoretically separated on a 12% sodium dodecyl
sulfate-polyacrylamide gel (SDS-PAGE). The protein
bands were revealed by staining with Coomassie blue
dye in 50% methanol and 10% glacial acetic acid fol-
lowed by destaining. In order to evaluate the proximal
tubular brush border integrity, leucine aminopeptidase
(LAP) activity was measured in urine using a spectroflu-
orometric assay after 1:30 and 1:60 dilution of the urine
samples with 50 mmol/L Tris HCl buffer (pH 7.6) [25]. Re-
sults were expressed as lmol 7-amido-4-methyl coumarin
(AMC) produced per mmol of urinary creatinine.
Measurement of renal angiotensin-converting
enzyme activity
About 50 mg of renal tissue was homogenized in 2 mL
of HEPES buffer (HEPES 50 mmol/L, MgCl2 10 mmol/L,
Triton X-100 0.1%, pH 7.4) and centrifugated at 12,000g
for 15 minutes at 4◦C. ACE activity was measured in
the supernatant by using a spectrophotometric method
[27]. Ten microliters of supernatant was mixed with
120 lL of the substrate hippuryl-L-histidyl-L-leucine
solution (Sigma-Aldrich, Bornem, Belgium) and incu-
bated for 15 minutes at 37◦C. Reaction was stopped
by adding 725 lL NaOH 0.28 mol/L, and L-histidyl-L-
leucine formed under the action of ACE was spectrofluo-
rimetrically quantified after being complexed with 50 lL
of O-phthaldialdehyde (excitation and emission wave-
lengths of 360 and 500 nm, respectively). ACE activity
was expressed as lmol of L-histidyl-L-leucine produced
per minute, and per milligram of protein.
Histopathologic study
For light microscopy, transversal paraffin-embedded
sections (5 lm thick) of the kidney were prepared and
stained with hematoxylin-eosin and Goldner’s trichrome.
Renal interstitial fibrosis was quantitated on Goldner’s
trichrome-stained sections by evaluating the interstitial
matrix expansion with a point-counting technique [28,
29]. Sections of paraffin-embedded renal tissue were vi-
sualized on a computer display with an Olympus DP50
camera connected to a light Olympus BX51 microscope
(Olympus Optical Co., Tokyo, Japan) at original mag-
nification of ×200. Up to 20 separate, nonoverlapping
microscopic fields of renal cortex from each rat were dig-
italized and saved on the hard disk of a personal com-
puter. The fractional volume occupied by the interstitial
fibrosis was evaluated by overlaying a 16 × 12-point grid
on the recorded digital image and defined as the ratio of
points lying within the fibrosis (stained in green) divided
by the total number of points. Values were averaged to
yield a mean score of each kidney (expressed as a per-
centage). Quantitation processes were made in a blinded
and randomized fashion.
Immunohistochemical staining
Mouse monoclonal antibodies were used for the de-
tection of a-smooth muscle actin (aSMA, Clone 1A4,
dilution 1:100; Dako, Glostrup, Denmark) and prolif-
erating cell nuclear antigen (PCNA, clone PC10, 1:100;
Dako). For labeling of collagens I and IV, samples were
incubated overnight with goat anti-type I collagen
(1:20 dilution, SouthernBiotech, Birmingham, AL, USA)
and anti-type IV collagen (1:40 dilution, Southern-
Biotech). These immunostainings were performed on de-
paraffinized and dehydrated 4% paraformaldehyde-fixed
sections.
Evaluation of monocyte/macrophage interstitial infil-
tration was done by using an immunohistochemical de-
tection with mouse monoclonal antibodies recognizing
the ED1 antigen (Serotec, Oxford, UK) on cryostat sec-
tions (8 lm thick) of frozen kidneys. Immunoperoxidase
staining was performed using a commercial kit (ABC kit,
Vector Laboratories, Inc., Burlingame, CA, USA). The
endogenous peroxidase activity was blocked in 1% hy-
drogen peroxide in methanol solution. Slides were rinsed
in TBS, and were incubated with 5% nonspecific horse
serum (Vector Laboratories) for 10 minutes in order to
prevent a cross-reaction of horse antimouse serum with
rat IgG. The sections were then rinsed in TBS, incubated
in avidin solution for 15 minutes, rinsed again in TBS,
and incubated in biotin solution for 15 minutes in order
to inactivate endogenous biotin. Sections were incubated
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overnight at 4◦C with the primary antibodies, then in-
cubated with biotinylated horse antimouse or antigoat
immunoglobulins (Vector Laboratories) according to the
primary antibody, and finally incubated with avidin/biotin
complex. The color development was performed with
the chromogen 3,3′-diaminobenzidene, and sections were
counterstained with hematoxylin. For negative controls,
the same protocol was performed omitting the first anti-
body.
To quantify the degree of ED-1–positive cells infiltra-
tion, up to 20 cortical fields (×200) were digitalized us-
ing Olympus DP50 camera mounted on Olympus BX51
microscope (Olympus Optical Co., Tokyo, Japan). The
ED-1 immunostaining was morphometrically measured
by evaluating the labeling index with a computer-assisted
image analyser system based on the NIH Image analysis
software (Scion Image version b4.0.2; Scion Corporation,
Frederick, MA, USA). The software enabled the opera-
tor to substract the background, and to set density thresh-
old values corresponding to the staining. The labeling
index was defined as the area above threshold divided by
the frame area, and represented the percentage of the to-
tal examined area that positively stained. Quantification
was performed blinded to the identity of the sections.
Statistical analyses
Results are expressed as mean ± SEM. Individual com-
parisons between two groups were performed with Stu-
dent t test. Comparison between multiple groups was
made using one-way analysis of variance (ANOVA) fol-
lowed by Bonferroni’s post-test. Nonparametric data
were compared by using the Kruskal-Wallis test, followed
by the Mann-Whitney rank test. Differences were consid-
ered significant if the P value was < 0.05.
RESULTS
Effect of ENA on blood pressure, renal ACE activity, and
biochemical parameters in the salt-depleted rat model of
AAN (protocol 1)
Thirty-five days of AA injections to salt-depleted rats
produced an increase in renal ACE activity without af-
fecting sBP (Table 2). Given to control rats, ENA signifi-
cantly reduced sBP and renal ACE activity. In AA groups
receiving ENA, renal ACE activity was also significantly
inhibited, whereas sBP was decreased without reaching
a significant statistical level (Table 2).
Renal function analyses performed on day 35 are listed
in Table 3. There were no significant differences between
control and ENA groups. Aristolochic acid-treated rats
exhibited a significant increase in plasma creatinine and
proteinuria, as well as a decrease in urinary LAP activ-
ity compared with controls. Whenever ENA was initiated
(from day 10 or 0), no change in renal function impair-
ment induced by AA was noticed.
Table 2. Effect of ACE inhibition on blood pressure and renal ACE
activity in AA-treated rats fed with a low sodium diet on day 35
(protocol 1)
Systolic blood Renal ACE activity
Rat groups pressure mm Hg lmol His-Leu/min/g protein
Control 115.5 ± 9.9 53.1 ± 21.6a
ENA 90.9 ± 5.3b 2.4 ± 2.4b
AA 126.4 ± 12.1 118.2 ± 32.2
AA + ENA 101.6 ± 9.6 4.6 ± 3.3b,c
AA + ENAd10 96.9 ± 5.7 4.0 ± 4.0b,c
Abbreviations are: ACE, angiotensin-converting enzyme; His-Leu, histidyl-
leucine; ENA, enalapril (10 mg/kg body wt) started from day 0; AA, aristolochic
acids (10 mg/kg body wt); ENAd10, enalapril (10 mg/kg body wt) started from
day 10. Data are the mean ± SEM for seven rats/group, except for control group
(N = 6).
aN = 5; one determination could not be performed.
bP < 0.01, compared with control rats.
cP < 0.05, compared with AA-treated rats.
Table 3. Effect of ACE inhibition on renal function in AA-treated
rats fed with a low sodium diet on day 35 (protocol 1)
Plasma Proteinuria Urinary LAP
creatinine g/mmol activity lmol
lmol/L creatinine AMC/mmol creatinine
Control 26.9 ± 1.8 0.11 ± 0.01 116.4 ± 4.8
ENA 33.3 ± 3.5 0.15 ± 0.02 100.6 ± 10.6
AA 63.9 ± 4.9a 0.35 ± 0.04b 17.6 ± 3.1b
AA + ENA 70.1 ± 8.1c 0.41 ± 0.05b 18.7 ± 1.3b
AA + ENAd10 80.9 ± 12.9c 0.44 ± 0.03b 26.9 ± 3.3b
Abbreviations are: LAP, leucine aminopeptidase; AMC, 7-amido-4-methyl
coumarin; ENA, enalapril (10 mg/kg body wt) started from day 0; AA,
aristolochic acids (10 mg/kg body wt); ENAd10, enalapril (10 mg/kg body wt)
started from day 10. Data are the mean ± SEM for seven rats/group, except for
control group (N = 6).
aP < 0.05, compared with control rats.
bP < 0.001, compared with control rats.
cP < 0.01, compared with control rats.
Effect of ENA on renal morphologic parameters in the
salt-depleted rat model of AAN (protocol 1)
In the control and ENA groups, no significant abnor-
mality was observed in the renal tissue samples obtained
on day 35. On the contrary, numerous foci of tubular atro-
phy and mononuclear cells infiltration, surrounded by se-
vere interstitial fibrosis, were found in the deep cortex, the
outer medulla, and the medullary rays from AA-treated
rats. The injured tubules showed a sustained regenera-
tive process, as reflected by an increase of PCNA-positive
proximal tubule cells (Fig. 1A and B). The tubulointer-
stitial lesions were also characterized by the presence of
a-SMA–positive myofibroblasts and the enlargement of
interstitium due to collagen type IV deposition (Fig. 1C
to F). As depicted in Figure 2A, the fractional volume
of interstitial fibrosis was dramatically increased in the
AA group. The treatment with ENA did not result in any
change of this AA-induced renal fibrosis.
Around the injured tubules, the renal interstitium
was infiltrated by ED-1 + monocytes/macrophages
after 35 days of AA injections. When given from day 10
to AA-treated rats, ENA induced a 35% reduction of
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Fig. 1. Light microscopy of immunostaining for proliferating cells (A, B), a-smooth muscle actin–positive myofibroblasts (C, D), and collagen type
IV (E, F). Photomicrographs (×400) of renal cortex from representative salt-depleted rats (protocol 1) receiving vehicle (A, C, E) and aristolochic
acids (B, D, F). Rats treated with aristolochic acids for 35 days showed foci of tubulointerstitial injuries characterized by regenerative PCNA-positive
tubular cells (B), the presence of a-SMA–positive myofibroblasts (D), and the enlargement of interstitium due to collagen type IV deposition (F).
macrophages infiltration. This reduction exceeded 50%
when ENA was administrated as early as day 0 (Fig. 2B).
Effect of the salt diet on the development of the rat model
of AAN (protocol 2)
As shown in Table 4 comparing AA-treated rats fed
with a normal sodium diet to those fed with a low sodium
diet, the urinary sodium excretion was significantly de-
creased in animals kept on low sodium diet. However, no
statistical difference was found between the two groups in
terms of sBP, renal ACE activity, plasma creatinine, pro-
teinuria, fractional volume of interstitial fibrosis, and ED-
1 positive cells infiltration. Histologic tubulointerstitial
injuries consisting in tubular atrophy and regeneration,
inflammatory and myofibroblast cell infiltration, intersti-
tial fibrosis, and collagen type IV deposition were found
in AA-treated rats, irrespective of the dietary sodium
intake.
1820 Debelle et al: Renin-angiotensin system and aristolochic acid nephropathy
6
4
2
12
10
8
0
Fr
ac
tio
na
l v
ol
um
e 
of
 
in
te
rs
tit
ia
l f
ib
ro
sis
, %
A
*
*
*
3.0
2.5
2.0
1.5
1.0
0.5
0.0
ED
-1
 +
 
la
be
lin
g 
in
de
x,
 %
B
*
*
*
#
Fig. 2. Semiquantitative evaluation of the fractional volume occupied
by interstitial fibrosis (A) and ED-1 + monocytes/macrophages infil-
tration (B) in the renal cortex (protocol 1). Values are expressed as
mean ± SEM from sodium-depleted rats given vehicle (control, N =
6), enalapril (ENA, N = 7), aristolochic acids (AA, N = 7), aristolochic
acids + enalapril started from day 0 (AA+ENA, N = 7), and aris-
tolochic acids + enalapril started from day 10 (AA+ENAd10, N = 7).
Symbols are: , control; , ENA; , AA; , AA + ENA; , AA +
ENAd10. ∗P < 0.01 vs. control and #P < 0.01 vs. AA.
Effect of the combined therapy (ENA+CSN) on blood
pressure, renal ACE activity, and biochemical parameters
in rats receiving a normal sodium diet and AA
(protocol 2)
Despite a significant increase in renal ACE activ-
ity, no significant change in sBP was observed in rats
treated by AA when compared to controls (Table 5).
By contrast, AA-intoxicated animals given the combined
therapy ENA+CSN showed a reduced sBP and an in-
hibition of renal ACE activity (Table 5). However, this
inhibition did not result in any change in renal func-
tional parameters such as plasma creatinine, protein-
uria and urinary LAP activity (Table 6). Of note, the
electrophoretic patterns of proteinuria observed in AA-
treated rats consisted in albuminuria and low-molecular-
weight proteins. These patterns were similar to those
found in control rats, as well as in animals treated with
the combined therapy ENA + CSN (data not shown).
Table 4. Effect of dietary sodium intake on the development of the
rat model of AA nephropathy on day 35 (protocol 2)
AA—normal sodium AA—low sodium
diet N = 6 diet N = 7
uNa/uCr 28.7 ± 2.2 5.5 ± 1.4a
sBP 148.6 ± 5.6 149.0 ± 5.6
Renal ACEa 167.8 ± 40.1 215.9 ± 69.1
pCr 40.4 ± 10.4 30.1 ± 5.5
uPr 0.33 ± 0.02 0.32 ± 0.04
Interstial fibrosis % 5.6 ± 0.4 6.8 ± 1.1
ED-1 + cells % 5.8 ± 1.0 3.9 ± 0.7
Abbreviations are: AA, aristolochic acids (10 mg/kg body wt); uNa/uCr,
urinary sodium excretion (mmol/mmol creatinine); sBP, systolic blood pressure
(mm Hg); ACEa, angiotensin-converting enzyme activity (lmol histidyl-leucine
produced/min/g protein); pCr, plasma creatinine (lmol/L); uPr, proteinuria
(g/mmol creatinine); ED-1 +, monocytes/macrophages. Data are the mean ±
SEM.
aP < 0.0001 compared with AA—normal sodium diet group.
Table 5. Effect of combined therapy (ENA + CSN) on blood
pressure and renal ACE activity in AA-treated rats fed with a normal
sodium diet on day 35 (protocol 2)
Systolic Renal ACE
blood pressure activity lmol
Rat groups mm Hg His-Leu/min/g protein
Control 140.1 ± 8.2 85.6 ± 10.8
ENA + CSN 110.6 ± 2.0a 3.16 ± 3.16b
AA 148.6 ± 9.2 167.8 ± 40.1c
AA + ENA + CSN 106.0 ± 3.9a,d 31.9 ± 17.8c,e
Abbreviations are: ACE, angiotensin-converting enzyme; His-Leu, histidyl-
leucine; ENA, enalapril (10 mg/kg body wt); CSN, candesartan cilexetil (7 mg/kg
body wt); AA, aristolochic acids (10 mg/kg body wt). Data are the mean ± SEM
for seven rats/group, except for AA group (N = 6).
aP < 0.01, compared with control rats.
bP < 0.001, compared with control rats.
cP < 0.05, compared with control rats.
dP < 0.001, compared with AA-treated rats.
eP < 0.01, compared with AA-treated rats.
Table 6. Effects of combined therapy (ENA + CSN) on renal
function in AA-treated rats fed with a normal sodium diet on day 35
(protocol 2)
Plasma Proteinuria Urinary LAP activity
creatinine g/mmol lmol AMC/mmol
Rat groups lmol/L creatinine creatinine
Control 15.9 ± 0.8 0.15 ± 0.01 45.7 ± 8.1
ENA + CSN 16.2 ± 0.9 0.13 ± 0.01 65.7 ± 18.5
AA 40.4 ± 10.4a 0.33 ± 0.02b 9.8 ± 2.6c
AA + ENA + CSN 37.4 ± 9.4c 0.30 ± 0.02b 10.0 ± 0.9b
Abbreviations are: LAP, leucine aminopeptidase; AMC, 7-amido-4-methyl
coumarin; ENA, enalapril (10 mg/kg body wt); CSN, candesartan cilexetil (7
mg/kg body wt); AA, aristolochic acids (10 mg/kg body wt). Data are the mean
± SEM for seven rats/group, except for AA group (N = 6).
aP < 0.05, compared with control rats.
bP < 0.001, compared with control rats.
cP < 0.01, compared with control rats.
Effect of the combined therapy (ENA+CSN) on
renal morphologic parameters in rats receiving a normal
sodium diet and AA (protocol 2)
No renal histopathologic change was found in the con-
trol and ENA+CSN groups. Typical morphologic find-
ings of AA-induced nephropathy consisting in tubular
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Fig. 3. Light microscopy of Goldner’s trichrome-stained sections (A, C, E, G) and immunostaining for ED1 + monocytes/macrophages (B, D, F,
H). Photomicrographs (×200) of renal cortex on day 35 from representative rats (protocol 2) given vehicle (A, B), aristolochic acids (C, D), and
aristolochic acids combined with enalapril plus candesartan (E, F), and on day 65 from representative rats (protocol 3) receiving AA for 35 days
and enalapril plus candesartan for 65 days (G, H).
atrophy, mononuclear cells infiltrate, and interstitial fi-
brosis (Fig. 3A to F) were observed in both AA and
AA+ENA+CSN groups. PCNA-postive proliferating
tubule cells, a-SMA myofibroblasts, and collagen type
IV deposition were also found. The ED-1 immunostain-
ing confirmed the accumulation of macrophages into the
renal interstitium from AA-treated rats compared with
control rats.
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Fig. 4. Semiquantitative evaluation of the fractional volume of inter-
stitial fibrosis (A) and ED-1 + monocytes/macrophages infiltration (B)
in the renal cortex. In the protocol 2, values are expressed as mean ±
SEM from rats fed with a normal sodium diet and given vehicle (con-
trol, N = 7), enalapril combined with candesartan (ENA + CSN, N =
7), aristolochic acids (AA, N = 6), and aristolochic acids treated with
enalapril plus candesartan (AA+ENA+CSN, N = 7) for 35 days. In the
protocol 3, values are expressed as mean ± SEM from rats fed with a
normal sodium diet and given aristolochic acids for 35 days (AA, N = 6)
alone or with enalapril plus candesartan for 65 days (AA+ENA+CSN,
N = 4). Symbols are: , control; , ENA + CSN; , AA; , AA +
ENA + CSN. ∗P < 0.001 vs. control; ∗∗P < 0.01 vs. control and #P <
0.01 vs. AA.
The fractional volume of interstitial fibrosis was
markedly increased to a similar extent in both AA groups,
untreated or treated with ENA+CSN (Fig. 4A). By con-
trast, this combined therapy administrated to AA-treated
rats induced a twofold decrease of monocyte/macrophage
infiltration (Fig. 4B).
Effect of the combined therapy (ENA+CSN) given for
up to 65 days on blood pressure, renal biochemical,
and morphologic parameters in rats receiving a normal
sodium diet and AA (protocol 3)
In the group of AA-intoxicated rats treated with ENA
+ CSN, two rats were found dead (one at day 18 due to
accidental water deprivation, and one at day 64 due to
severe hypotension). Typical tubulointerstitial injuries as
described above were observed in both AA-intoxicated
Table 7. Effect of the combined therapy (ENA+CSN) on blood
pressure, renal biochemical, and morphologic parameters in rats
receiving a normal sodium diet and AA on day 65 (protocol 3)
AA for 35 days +
AA for 35 days ENA + CSN for 65 days
sBP 133.7 ± 5.7 91.2 ± 3.9a
pCr 25.7 ± 1.1 25.2 ± 1.6
uPr 0.17 ± 0.01 0.14 ± 0.04
uLAP 13.6 ± 1.3 8.9 ± 2.0
Abbreviations are: AA, aristolochic acids (10 mg/kg body wt); ENA, enalapril
(10 mg/kg body wt); CSN, candesartan cilexetil (7 mg/kg body wt); sBP, systolic
blood pressure (mm Hg); pCr, plasma creatinine (lmol/L); uPr, proteinuria
(g/mmol creatinine); uLAP, urinary leucine aminopeptidase activity (lmol
7-amido-4-methyl coumarin produced/mmol creatinine). Data are the mean ±
SEM for six rats/group, except for AA + ENA + CSN group, in which two rats
were found dead.
aP < 0.001.
rat groups, given (Fig. 3G and H) or not given the ENA
+ CSN therapy. When ENA + CSN were administrated
to AA-intoxicated rats, sBP was decreased on day 65,
but biochemical (Table 7) and morphologic (Fig. 4) alter-
ations induced by AA were unchanged.
DISCUSSION
In the past decade, a new type of rapidly progres-
sive interstitial fibrosis has been reported after exposure
to nephrotoxic aristolochic acids contained in plants of
Aristolochia species (reviewed in [9]). Recently, a repro-
ducible short-term model of chronic AAN was developed
in salt-depleted male Wistar rats [11, 25]. As demon-
strated for the cyclosporine A–induced nephropathy rat
model [12], stimulation of the intrarenal RAS via sodium
depletion seemed to be prerequired to enhance the re-
nal interstitial fibrosis process. In the present study, we
demonstrated that similar tubulointerstitial insults could
be obtained in AA-treated rats fed a normal sodium diet
compared to a salt-depletion conditioning. Moreover, the
RAS blockade with ACE inhibitor ± AT1RA concomi-
tant to AA-injections for 35 days significantly reduced
the macrophages infiltration, but had no beneficial ef-
fect on the renal functional impairment or interstitial
fibrosis. The dual RAS blockade therapy given for an
extended period of 65 days also failed to prevent AA-
induced nephropathy in this model.
Our initial model of AAN was designed on the ba-
sis of the cyclosprine A–induced nephropathy rat model,
suggesting that RAS stimulation was important in the in-
duction of tubulointerstitial lesions [11]. Interestingly, the
renal ACE activity was not enhanced by the salt restric-
tion. These data are consistent with recent experimen-
tal results showing that salt depletion in rats increased
the renin activity and angiotensin I and II production
without affecting ACE activity [30]. By contrast, the re-
nal ACE activity was increased in rats intoxicated by
AA with the same extent in both dietary sodium condi-
tions. Although intrarenal Ang II levels were not directly
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measured, we can consider that elevated ACE activity
reflected a stimulation of the local RAS and an enhance-
ment of Ang II generation. This activation of the in-
trarenal RAS could derive from two main origins. First,
in response to renal injurious stimuli, proximal tubule
cells may express mRNA for renin, angiotensinogen, and
ACE [31]. Second, several studies have shown that mono-
cytes/macrophages can express all the components of the
RAS and produce Ang II [32]. Since Ang II was demon-
strated to be a chemotactic factor [33, 34], the activated
inflammatory cells may contribute in turn to the progres-
sion and perpetuation of inflammation.
In the present rat model of AAN, the sodium de-
pletion conditioning did not exacerbate the activation
of intrarenal ACE activity or the severity of mono-
cytes/macrophages interstitial infiltration. In parallel,
similar tubulointerstitial injuries and renal impairment
were found in AA-treated rats, irrespective of the di-
etary sodium intake. The tubular lesions, resulting from
an imbalance between death and regenerating cells, were
located in the deep cortex and the outer stripe of outer
medulla with extension along the medullary rays, con-
firming that the pars recta of proximal tubule was the
main target of AA-related nephrotoxicity [35, 36]. Foci
of injured tubules were surrounded by infiltrating mono-
cytes/macrophages and a-SMA myofibroblasts, as well
as interstitial fibrosis characterized by collagen type IV
deposition. Growing evidence suggests that a-SMA my-
ofibroblasts, the main cells involved in the accumulation
of interstitial extracellular matrix, are derived from tubu-
lar epithelium under pathologic conditions by a process of
epithelial to mesenchymal transition [37, 38]. It is interest-
ing to note that glomerular structures, as well as afferent
and efferent arterioles, were not affected by AA-induced
nephrotoxicity. These histologic findings were quite sim-
ilar to those observed in patients suffering from the so-
called Chinese herbs nephropathy (CHN) [4]. In renal
tissue samples from CHN patients, the interstitial fibro-
sis was more extensive than in this rat model, with major
loss of tubules and variable degree of inflammatory in-
filtrates. The glomeruli were relatively spared, whereas
interlobular and afferent arterioles showed thickening of
their walls. These differences in the severity of the histo-
logic lesions actually reflect a more advanced stage of the
disease in CHN patients.
Since intrarenal ACE activity was demonstrated to be
enhanced, we hypothesized that ACE inhibitor, com-
bined or not with AT1RA, could exhibit renoprotec-
tive effects. It has been largely demonstrated that RAS
blockade attenuated the glomerulosclerosis and tubu-
lointerstitial fibrosis jointly to reduce proteinuria and
glomerular filtration rate (GFR) decline in a broad range
of experimental renal diseases models, such as anti-
Thy1 mesangial proliferative glomerulonephritis [39],
chronic aminonucleoside nephrosis [40], passive Hey-
mann nephritis [41], diabetic nephropathy [42], re-
nal mass reduction [43], obstructive nephropathy [44],
and cyclosporine nephropathy [45]. Nevertheless, in the
present rat model of chronic interstitial fibrosis, RAS
blockade by either an ACE inhibitor alone or combined
with an AT1RA did not prevent the renal function im-
pairment induced by AA. One possible explanation could
be insufficient doses of ACE inhibitor or AT1RA given
to AA-intoxicated rats. However, RAS seemed to be cor-
rectly blocked at the dose of 10 mg/kg body wt of ENA
and 7 mg/kg body wt of CSN, as attested by a sustained de-
crease of sBP and an almost complete inhibition of renal
ACE activity. Another explanation for the lack of positive
effect on plasma creatinine could be the fall of sBP due to
RAS blockade, resulting in reduced renal perfusion and a
decrease of GFR. Interestingly, similar observations were
also reported in the cyclosporine A–induced nephropa-
thy treated with ENA or losartan or a combination of
these drugs [45].
Nephroprotective effects of RAS blockade are largely
attributed to its ability to reduce proteinuria and, in par-
ticular, albuminuria. Indeed, proteins filtered in exces-
sive quantities and reabsorbed by proximal tubule cells
cause injury by lysosome rupture, and induce phenotypic
changes, which in turn lead to interstitial inflammatory
reaction and fibrosis [46]. Rats intoxicated with AA de-
veloped after 35 days a moderate proteinuria with an elec-
trophoretic pattern mainly comparable to this observed
in control rats. It is reasonable to think that AA-induced
proteinuria was the consequence of proximal tubular
damage, rather than glomerular barrier alteration, which
might explain the absence of effects of RAS blockade on
this proteinuria.
A striking finding of our study was the severe inter-
stitial accumulation of monocytes/macrophages induced
by AA. These mononuclear cells, found in most of pro-
gressive renal diseases irrespectively of their underly-
ing cause, are considered to be an important source of
fibrosis-promoting growth factors, vasoactive molecules,
and even matrix proteins [47, 48]. In several models
of renal injury, RAS blockade results in a reduction of
macrophage infiltration and fibrosis [49–51]. Similarly,
in the present rat model of AAN, a significant reduc-
tion of monocytes/macrophages infiltration was observed
following ENA or ENA plus CSN administration to
AA-treated rats. However, ED-1 staining does not dis-
tinguish activated macrophages from inactive monocytes,
and thus, the contribution of mononuclear cells infiltra-
tion in the pathogenesis of AAN is largely unknown and
remains to be investigated. Despite this putative benefi-
cial effect of the RAS blockade, renal interstitial fibrosis
and chronic renal failure were not prevented on day 35, as
well as on day 65. One may object that renal fibrosis was
evaluated by a semiquantitative scoring system, which
could not be able to detect some slight changes. Anyway,
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renal failure was obviously unaffected by RAS blockade,
as reflected by similar elevated plasma creatinine in AA
groups given or not the therapy.
CONCLUSION
The absence of enhancing effect of RAS stimulation on
AAN allows us to simplify the protocol design for further
experiments by omiting the salt-depletion procedure. On
the other hand, the RAS blockade with an ACE inhibitor
alone or combined with an AT1RA does not improve re-
nal functional parameters and tubulointerstitial fibrosis
in this rat model of AAN, despite a significant decrease
in the monocytes/macrophages infiltration. Our data sug-
gest that some pathways from renal injury to progressive
fibrosis may be RAS independent.
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